Dr. McGregor on the Evolving Treatment Landscape of RCC

Partner | Cancer Centers | <b>Dana Farber</b>

Bradley McGregor, MD, discusses the evolving treatment landscape of renal cell carcinoma.

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses the evolving treatment landscape of renal cell carcinoma (RCC).

The field is expanding to evaluate new pathways, targets, and combination therapies to improve outcomes for patients with RCC, McGregor explains.

Historically, the treatment paradigm was limited until the advent of TKIs, says McGregor. Moreover, the addition of cabozantinib (Cabometyx) to the second-line setting was important as the agent demonstrated a survival benefit versus sunitinib (Sutent).

Additionally, nivolumab (Opdivo) has been a welcomed addition to the armamentarium, McGregor continues.

In the frontline setting, multiple combination regimens, including nivolumab plus ipilimumab (Yervoy), have demonstrated overall survival benefit compared with TKI monotherapy, concludes McGregor.